论文部分内容阅读
目的:探讨聚甲基丙烯酸甲酯(PMMA)骨水泥加入抗肿瘤药物后物理和力学性能的变化,以及抗肿瘤药物在体外释放的情况。方法:在40 g骨水泥中分别加入50 mg多柔比星、20 mg唑来膦酸,并设立单纯的骨水泥组作为对照。在无菌条件下将骨水泥按照ISO5833:2002《外科植入物——丙烯酸类树脂骨水泥》的标准制成各种试件,测定其抗压强度、抗弯模量和抗弯强度。同时将试件进行浸泡洗提,检测其药物的释放情况。结果:与对照组相比,骨水泥的物理和力学性能没有明显的改变,对照组和实验组骨水泥的抗压强度、抗弯模量、抗弯强度,差异无统计学意义,P>0.05。两种药物均能从骨水泥中缓慢的释放出来,药物的释放规律及释放量基本相同,多柔比星释放总量占药物初始剂量的0.83%,唑来膦酸释放总量占药物初始剂量的0.66%。结论:抗肿瘤药物能有效地从骨水泥中缓慢的释放,40 g骨水泥中加入<1 g的药物不会影响骨水泥的物理和力学性能,PMMA骨水泥适合作为抗肿瘤药物的缓释载体。
Objective: To investigate the changes of physical and mechanical properties of polymethylmethacrylate (PMMA) cements after the addition of antitumor drugs, and the release of antitumor drugs in vitro. Methods: 50 mg doxorubicin and 20 mg zoledronic acid were added to 40 g bone cement respectively, and pure bone cement group was set as control. Under aseptic conditions, cements were made into various specimens according to ISO 5833: 2002 “Surgical implants - Acrylic cements” and their compressive strength, flexural modulus and flexural strength were measured. At the same time, the specimen was soaked and eluted to test the release of the drug. Results: Compared with the control group, the physical and mechanical properties of bone cement did not change significantly. The compressive strength, flexural modulus and flexural strength of bone cement in the control group and the experimental group were not significantly different (P> 0.05) . Both drugs can be slowly released from the bone cement, drug release and release of the same basic pattern, the total release of doxorubicin drugs accounted for 0.83% of the initial dose of zoledronic acid release of the total amount of the initial drug dose Of 0.66%. CONCLUSIONS: The anti-tumor drugs can be effectively released from bone cement. The addition of <1 g of drug to 40 g of bone cement does not affect the physical and mechanical properties of bone cement. PMMA bone cement is suitable as a sustained-release carrier for anti-tumor drugs .